期刊文献+

维持血液透析患者血红蛋白达标情况分析 被引量:4

Hemoglobin level analysis in hemodialysis patients
原文传递
导出
摘要 目的了解维持血液透析患者贫血治疗达标情况并分析其影响因素。方法选择我院规律血液透析患者73例。按血红蛋白(hemoglobin,Hb)水平将患者分为3组:A组为Hb≥130 g/L患者;B组为110 g/L≤Hb<130g/L患者;C组为Hb<110 g/L患者。透析前采血检测肾功能、血常规、电解质、白蛋白(albumin,Alb)、C反应蛋白(C-reactive protein,CRP)、β2-微球蛋白(β2-microglobulin,β2-MG)、血清全段甲状旁腺激素(intact parathyroid hormone,iPTH)、血清铁蛋白(serum ferritin,SF)等参数。记录最近4周重组人红细胞生成素(recombinant human erythropoietin,r-HuEPO)的应用总量,以每周应用总量同红细胞压积(hematocrit,Hct)的比值(r-HuEPO dosage to Hct,EPO/Hct)作为评价r-HuEPO低反应的指标。比较3组患者上述指标的差别,分析各因素与Hb的相关性。结果①73例患者中,Hb≥110 g/L者62例,占全部患者的84.93%。②EPO/Hct比值,B组患者明显高于A组患者(P<0.05)。③C组患者EPO/Hct比值、CRP、β2-MG及iPTH水平均高于A组和B组(P<0.05)。④其余各项指标三组间差异无统计学意义(P>0.05)。⑤单因素相关分析,Hb与ALB呈显著正相关(P<0.05);与EPO/Hct、β2-MG、CRP及iPTH呈显著负相关(P<0.05)。⑥多因素逐步线性回归分析:EPO/Hct、CRP、Alb和β2-MG是Hb的独立影响因素[标准回归系数(Beta)分别为-1.607,-3.391,0.612,-1.019]。结论 r-HuEPO低反应性是贫血治疗不达标的主要原因,患者微炎症水平、营养状态及中分子毒素的清除不足可能是其危险因素。 Objective To investigate the hemoglobin level in hemodialysis patients and its factors of influence.Methods Seventy-three hemodialysis patients were divided into group A(Hb≥130 g/L),B(110 g/L≤Hb130 g/L) and C(Hb110 g/L) according to the plasma hemoglobin level.A series of biochemical tests were performed before dialysis such as renal function,blood routine,electrolysis,albumin(Alb),C-reactive protein(CRP),β2-microglobulin(β2-MG),serum intact parathyroid hormone(iPTH) and serum ferritin(SF).The total applied amount of r-HuEPO in the recent four weeks and the ratio of the applied amount of r-HuEPO per week and Hct were recorded as evaluation indicators of low response for r-HuEPO.These indicators were compared between the three groups;the correlation between these factors and Hb was analyzed.Results ①Sixty-two patients with Hb≥110 g/L accounted for 84.93% of the total patients.②The amount of erythropoietin/hematocrit(EPO/Hct) ratio in group B was higher than that in group A(P0.05).③EPO/Hct ratio,ALB,CRP,β2-MG and iPTH in group C were higher than those in group A and B respectively.④There was no difference in other indicators between the three groups(P0.05).⑤By univariate correlation analysis,Alb was positively correlated with Hb.However,EPO/HCT,β2-MG,CRP and iPTH were negatively correlated with Hb(P0.05).⑥By multivariate stepwise linear regression analysis,Hb level was strongly related to EPO/Hct,CRP,Alb,β2-MG and iPTH.The standard regression coefficient(Beta) was-1.607,-3.391,0.612 and-1.019,respectively.Conclusions The low response for r-HuEPO is the main reason for non-compliance for anemia treatment.The level of micro-inflammation,nutritional status and inadequate removal of toxins may be the risk factors.
出处 《军事医学》 CAS CSCD 北大核心 2012年第2期147-149,共3页 Military Medical Sciences
关键词 血液透析 肾性贫血 血红蛋白 红细胞生成素 C反应蛋白质 危险因素 hemodialysis renal anemia hemoglobin erythropoietin C-reaction protein risk factors
  • 相关文献

参考文献4

二级参考文献50

  • 1北京市血液透析质量控制和改进中心.北京市血液透析登记2007年年度报告[R].北京:北京市血液透析质量控制和改进中心,2009.
  • 2KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease[J].Am J Kidney Dis,2006,47:S1-145.
  • 3Mathieu CM,Teta D,Lotscher N,et al.Optimal and continu-ons anaemia control in a cohort of dialysis patients in Switzerland[J].BMC Nephrol,2008,11:9-16.
  • 4Pisoni RL,Bragg-Gresham JL,Young EW,et al.Anemia manangement and outcomes from 12 countries in the dialysis outcomes and practice patttems study(DOPPS)[J].Am J Kid-ney Dis,2004:94-111.
  • 5Jacobs C,Frei D.Perkins AC.Result of the European Survey on Anaemia management 2003(ESAM 2003):Current status of anaemia management in dialysis patient,factors affecting epoetin dosage and changes in anaemia manangement over the last 5 years[J].Nephrol Dial Transplant,2005,20:iii3-iii24.
  • 6Gebay C,Kushner I.N Engl J Med, 1999;340:448 ~454.
  • 7Mank B, Pepys, Abi Berger. BMJ, 2001 ;322.4 ~ 5.
  • 8Shine B,de Beer FC,Pepys MB.Clin Chem Acta, 1981 ; 117:13~ 23.
  • 9Macy EM, Hayes TE,Tracy RP. Clin Chem,1997;43:52 ~ 58.
  • 10Koenig W,Sund M, Froelich M,et al.Circulation, 1999;99:237 ~ 242.

共引文献96

同被引文献34

  • 1劳海燕,杨敏,万波,郑志伟,刘双信,张燕丽.影响维持性血液透析患者血色素达标相关因素分析[J].岭南心血管病杂志,2011,17(S1):168-169. 被引量:1
  • 2胡锋,胡子燕.大剂量促红细胞生成素治疗肾性贫血15例[A].//2011年全国医药学术论文交流会论文集[C].2011:45-46.
  • 3栾迅飞.维持性透析患者肾性贫血现状分析[D].沈阳:中国医科大学,2011.
  • 4刘金彦.高通量血液透析和血液灌流联合血液透析对维持血透患者微炎症状态的影响的临床观察[A].//第5届全国疑难及重症肝病大会论文集[C].2010:275-276.
  • 5MacdongallIC,RobsonR,OpatroaS,etal.Pharmacokineticsandphar-macodynamicsofintravenoussadsubcutaneouscontinuouserythropoi-etinreceptoractivator(C.E.R.A.)inpatientswithchronickidneyDisease[J].ClinJAmSueNephrol,2006,23(1):1211-1215.
  • 6Maedongall IC, Robson R, Opatroa S, et al. Pharmacokineties and pharmacodynamics of intravenous sad subcutaneous con- tinuous erythropoietin receptor activator (C. E. R.A.) in pa-tients with chronic kidney disease E J]. Clin J Am Sue Nephrol, 2006,23(1) : 1211-1215.
  • 7Roger SD,Locatelli F,Woitas RP, et al . C.E.R.A.once every 4 weeks corrects anaemia and maintains haemoglobin in pa- tients with chronic kidney disease not on dialysis[J~. Nephrol Dial Transplant, 2011,26(12) ~3980-3986.
  • 8李寒,王世相.静脉用蔗糖铁注射液治疗维持性透析患者肾性贫血的临床研究[J].中华医学杂志,2009,89(7):457-462. 被引量:9
  • 9张明,高鑫,谷红霞,乔静,魏春华,何芳娟.大剂量促红细胞生成素治疗肾性贫血[J].实用医药杂志,2009,26(5):1-2. 被引量:10
  • 10王伟,方静,董俊邑,梁江红,郁昊,卢小琼.维持性血液透析患者钙磷代谢异常调查[J].实用医院临床杂志,2010,7(2):75-78. 被引量:6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部